ProHeart 12 keeps the focus on year-long heartworm compliance

ProHeart 12, Zoetis’ extended-release injectable moxidectin product, is being highlighted again in sponsored veterinary trade coverage as a one-dose option that gives dogs 12 months of heartworm prevention. The product has been FDA-approved since July 2, 2019, for dogs 12 months and older, and it’s also approved to treat existing larval and adult hookworm infections. FDA records and the current product labeling show it remains subject to a Risk Minimization Action Plan, including training and certification requirements for veterinary teams who administer it. (fda.gov)

Why it matters: For veterinary professionals, the real story isn’t just convenience marketing. Long-acting injectable prevention directly addresses one of the biggest weak points in heartworm control: client adherence. The American Heartworm Society says preventive doses sold in the U.S. have declined even as pet numbers rise, and CAPC continues to recommend annual testing, including for dogs already on prevention. Published efficacy data for ProHeart 12 found 100% prevention in two laboratory studies and a 297-dog U.S. field study, while additional research has pointed to strong performance of moxidectin-based prevention even in the context of emerging macrocyclic lactone resistance concerns. (heartwormsociety.org)

What to watch: Expect continued discussion around compliance-driven prevention, annual testing protocols, and how clinics position injectable options as heartworm incidence remains a nationwide concern. (heartwormsociety.org)